AcelRx Pharmaceuticals, Inc. (ACRX)
ACRX Price and Sentiment
ACRX Latest news
AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
2021-10-02 00:22AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
2021-09-10 15:19HAYWARD, Calif., Sept. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C.
Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event
2021-08-30 08:30HAYWARD, Calif., Aug. 30, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a study evaluating sufentanil sublingual tablet 30 mcg (SST) for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery (MCS) conference on Friday, August 27 th at the Miami Beach Convention Center in Miami Beach, Florida.
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event
2021-08-26 08:30HAYWARD, Calif., Aug. 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the effects of administering sufentanil sublingual tablet 30 mcg (SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.
5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021
2021-08-18 15:30Analysts say these are penny stocks to buy. Do you agree?
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2021 Results - Earnings Call Transcript
2021-08-16 19:19AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2021 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates
2021-08-16 19:03AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results
2021-08-16 16:01HAYWARD, Calif., Aug. 16, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2021 financial results.
Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm
2021-08-12 16:01New York, New York--(Newsfile Corp. - August 12, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)The company or its officers and directors made false and/or misleading statements and/or failed to disclose...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
2021-08-09 16:30NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.